These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19239363)

  • 21. Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus.
    Thuret I; Chaix ML; Tamalet C; Reliquet V; Firtion G; Tricoire J; Rabaud C; Frange P; Aumaître H; Blanche S
    AIDS; 2009 Nov; 23(17):2364-6. PubMed ID: 19823069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Raltegravir: the first HIV type 1 integrase inhibitor.
    Hicks C; Gulick RM
    Clin Infect Dis; 2009 Apr; 48(7):931-9. PubMed ID: 19231980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.
    Llibre JM; Buzón MJ; Massanella M; Esteve A; Dahl V; Puertas MC; Domingo P; Gatell JM; Larrouse M; Gutierrez M; Palmer S; Stevenson M; Blanco J; Martinez-Picado J; Clotet B
    Antivir Ther; 2012; 17(2):355-64. PubMed ID: 22290239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.
    Canducci F; Marinozzi MC; Sampaolo M; Boeri E; Spagnuolo V; Gianotti N; Castagna A; Paolucci S; Baldanti F; Lazzarin A; Clementi M
    J Antimicrob Chemother; 2010 Mar; 65(3):425-33. PubMed ID: 20056687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients.
    Caby F; Valin N; Marcelin AG; Schneider L; Andrade R; Guiguet M; Tubiana R; Canestri A; Valantin MA; Peytavin G; Pacanowski J; Morand-Joubert L; Calvez V; Girard PM; Katlama C
    Scand J Infect Dis; 2010 Jul; 42(6-7):527-32. PubMed ID: 20222846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emergence of raltegravir-resistant HIV-1 in the central nervous system.
    Watanabe K; Honda M; Watanabe T; Tsukada K; Teruya K; Kikuchi Y; Oka S; Gatanaga H
    Int J STD AIDS; 2010 Dec; 21(12):840-1. PubMed ID: 21297097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
    Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
    Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.
    Salgado M; Toro C; Simón A; Garrido C; Blanco F; Soriano V; Rodés B
    J Clin Virol; 2009 Oct; 46(2):173-5. PubMed ID: 19625211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful integrase inhibitor-based highly active antiretroviral therapy for a multidrug-class-resistant HIV type 1 group O-infected patient in Cameroon.
    Aghokeng AF; Kouanfack C; Peeters M; Mpoudi-Ngole E; Delaporte E
    AIDS Res Hum Retroviruses; 2013 Jan; 29(1):1-3. PubMed ID: 22889147
    [No Abstract]   [Full Text] [Related]  

  • 30. Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.
    Passaes CP; Guimarães ML; Cardoso SW; Pilotto JH; Veloso V; Grinsztejn B; Morgado MG
    J Med Virol; 2012 Dec; 84(12):1869-75. PubMed ID: 23080489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme.
    Florence E; De Wit S; Castagna A; Ribera E; Hill A; Vanaken H; van Delft Y; Marks S
    Int J STD AIDS; 2010 Mar; 21(3):224-5. PubMed ID: 20071441
    [No Abstract]   [Full Text] [Related]  

  • 32. In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen.
    Souza Cavalcanti J; Minhoto Lança A; de Paula Ferreira JL; da Eira M; de Souza Dantas DS; de Macedo Brígido LF
    Antiviral Res; 2012 Jul; 95(1):9-11. PubMed ID: 22564967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.
    Yazdanpanah Y; Fagard C; Descamps D; Taburet AM; Colin C; Roquebert B; Katlama C; Pialoux G; Jacomet C; Piketty C; Bollens D; Molina JM; Chêne G;
    Clin Infect Dis; 2009 Nov; 49(9):1441-9. PubMed ID: 19814627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High frequency of dolutegravir resistance in patients failing a raltegravir-containing salvage regimen.
    Cavalcanti Jde S; Ferreira JL; Guimarães PM; Vidal JE; Brigido LF
    J Antimicrob Chemother; 2015 Mar; 70(3):926-9. PubMed ID: 25386009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug susceptibility to etravirine and darunavir among Human Immunodeficiency Virus Type 1-derived pseudoviruses in treatment-experienced patients with HIV/AIDS in South Korea.
    Kwon OK; Kim SS; Rhee JE; Kee MK; Park M; Oh HR; Choi JY
    Virol J; 2015 Apr; 12():53. PubMed ID: 25879840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression.
    Santos JR; Llibre JM; Ferrer E; Domingo P; Imaz A; Moltó J; Martin-Iguacel R; Caum C; Podzamczer D; Clotet B
    HIV Clin Trials; 2009; 10(6):432-8. PubMed ID: 20133273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. No residual activity of raltegravir after development of 148 complex mutations in vivo.
    Khanlou H; Sayana S; Acosta E
    J Int Assoc Physicians AIDS Care (Chic); 2008; 7(6):281-2. PubMed ID: 19164138
    [No Abstract]   [Full Text] [Related]  

  • 38. Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study.
    Lê MP; Valantin MA; Assoumou L; Soulie C; Le Mestre S; Weiss L; Yazdanpanah Y; Molina JM; Bouchaud O; Raffi F; Reynes J; Calvez V; Marcelin AG; Costagliola D; Katlama C; Peytavin G;
    Pharmacotherapy; 2019 Apr; 39(4):514-520. PubMed ID: 30815916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimal sequence variability of the region of HIV-1 integrase targeted by the Abbott RealTime HIV-1 viral load assay in clinical specimens with reduced susceptibility to raltegravir.
    Young TP; Napolitano LA; Paquet AC; Parkin NT; Fransen S; Trinh R; Haddad M; Hackett J; Cloherty GA
    J Virol Methods; 2013 Nov; 193(2):693-6. PubMed ID: 23892128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
    Dailly E; Allavena C; Bouquié R; Deslandes G; Raffi F; Jolliet P
    AIDS Res Hum Retroviruses; 2013 Jan; 29(1):42-6. PubMed ID: 23148588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.